A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

Summary

The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.

Timeline

Start

2022-11-14

Primary completion

2024-01-10

Completion

2024-01-10

Outcome

Outcome not reported

Stopped: “The study was terminated due to a change in risk/benefit ratio, which no longer favoured continued development.”

Drugs

Indications